Celltrion Inc. (KOSDAQ:068270) gained W1,750 to W41,450 last week after submitting an application to FDA for Remsima infliximab, a biosimilar of autoimmune drug Remicade from Johnson & Johnson (NYSE:JNJ) and Merck & Co. Inc. (NYSE:MRK). According to Celltrion, the application is the first biosimilar mAb application to be submitted in the U.S.

Celltrion partner Hospira Inc. (NYSE:HSP) gained $0.64 to $55.02 last week